Glycemic targets and medication limitations for type 2 diabetes mellitus in the older adult

Consultant Pharmacist

Volumn 29, Issue 2, 2014, Pages 110-123

  Thompson, Angela M ^a   Linnebur, Sunny A ^b   Vande Griend, Joseph P ^c   Saseen, Joseph J ^c,d  

^a UNIVERSITY OF WYOMING SCHOOL OF PHARMACY   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d Department of Chemistry and Biochemistry   (United States)

Author keywords

Aged; Diabetes mellitus; Food and drug administration; Geriatrics; Hypoglycemia; Insulin; Thiazolidinediones; Type 2 diabetes mellitus

Indexed keywords

A1C = GLYCATED HEMOGLOBIN; AACE = AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS; ADA = AMERICAN DIABETES ASSOCIATION; AGED; AUC = AREA UNDER THE CURVE; CLCR = CREATININE CLEARANCE; CMAX = MAXIMUM CONCENTRATION; CV = CARDIOVASCULAR; DIABETES MELLITUS; DM = DIABETES MELLITUS; DPP-IV = DIPEPTIDYL PEPTIDASE; EASD = EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES; FDA = FOOD AND DRUG ADMINISTRATION; FOOD AND DRUG ADMINISTRATION; GERIATRICS; GFR = GLOMERULAR FILTRATION RATE; GI = GASTROINTESTINAL; GLP = GLUCAGON-LIKE PEPTIDE; HYPOGLYCEMIA; INSULIN; M = METER; MIN = MINUTE; NPH = NEUTRAL PROTAMINE HAGEDORN; NYHA = NEW YORK HEART ASSOCIATION; SCR = SERUM CREATININE; T2DM = TYPE 2 DIABETES MELLITUS; THIAZOLIDINEDIONES; TYPE 2 DIABETES MELLITUS; TZD = THIAZOLIDINEDIONE; UKPDS = UNITED KINGDOM PROSPECTIVE DM STUDY;

AGE FACTORS; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; PRACTICE GUIDELINES AS TOPIC;

EID: 84894234235     PISSN: 08885109     EISSN: None     Source Type: Journal    
DOI: 10.4140/TCP.n.2014.110     Document Type: Review

References (79)

1. Federal Interagency Forum on Aging-Related Statistics. Older Americans 2010: Key Indicators of Well-Being. Federal Interagency Forum on Aging-Related Statistics. Washington, DC: U.S. Government Printing Office; July 2010. Available at www.agingstats.gov. Accessed October 13, 2011.
2. American Diabetes Association. Diabetes Statistics. Available at http://www.diabetes.org/diabetes-basics/diabetes-statistics/. Accessed October 13, 2011.
3. Boyle JP, Honeycutt AA, Narayan KM et al. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. Diabetes Care 2001;24:1936-40. (Pubitemid 33716504)
4. Standards of medical care in diabetes-2012. Diabetes Care 2012;35 Suppl 1:S11-63.
5. Standards of medical care in diabetes-2013. Diabetes Care 2013;36 Suppl 1:S11-66.
6. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:854-65.
7. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-53.
8. Gerstein HC, Miller ME, Byington RP et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59. (Pubitemid 351831356)
9. Patel A, MacMahon S, Chalmers J et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72. (Pubitemid 351831357)
10. Duckworth W, Abraira C, Moritz T et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-39.
11. Holman R, Paul SK, Bethel MA et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89.
12. Brown AF, Mangione CM, Saliba D et al. Guidelines for improving the care of the older person with diabetes mellitus. J Am Geriatr Soc 2003;51:S265-80. (Pubitemid 36535105)
13. Kirkman MS, Briscoe VJ, Clark N et al. Diabetes in older adults. Diabetes Care 2012;35:2650-64.
14. Newman SC, Hassan AI. Antidepressant use in the elderly population in Canada: results from a national survey. J Gerontol A Biol Sci Med Sci 1999;54:M527-30. (Pubitemid 29534075)
15. Greene DA, Stevens MJ, Feldman EL. Diabetic neuropathy: scope of the syndrome. Am J Med 1999;107:2S-8S.
16. Brown JS, Seeley DG, Fong J et al. Urinary incontinence in older women: who is at risk? Study of Osteoporotic Fractures Research Group. Obstet Gynecol 1996;87:715-21.
17. Ueda T, Tamaki M, Kageyama S et al. Urinary incontinence among community-dwelling people aged 40 years or older in Japan: prevalence, risk factors, knowledge and self-perception. Int J Urol 2000;7:95-103. (Pubitemid 30167060)
18. Cukierman T, Gerstein HC, Williamson JD. Cognitive decline and dementia in diabetes-systematic overview of prospective observational studies. Diabetologia 2005;48:2460-9. (Pubitemid 41738208)
19. Rosenstock J. Management of type 2 diabetes mellitus in the elderly: special considerations. Drugs Aging 2001;18:31-44. (Pubitemid 32182131)
20. Matyka K, Evans M, Lomas J et al. Altered hierarchy of protective responses against severe hypoglycemia in normal aging in healthy men. Diabetes Care 1997;20:135-41. (Pubitemid 27051549)
21. Budnitz DS, Lovegrove MC, Shehab N et al. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 2011;365:2002-12.
22. Handelsman Y, Mechanick JI, Blonde L et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract 2011;17 Suppl 2:1-53.
23. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-79.
24. Yau CK, Eng C, Cenzer IS et al. Glycosylated hemoglobin and functional decline in community-dwelling nursing home-eligible elderly adults with diabetes mellitus. J Am Geriatr Soc 2012;60:1215-21.
25. Ismail-Beigi F, Moghissi E, Tiktin M et al. Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med 2011;154:554-9.
26. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203.
27. Rodbard HW, Jellinger PS, Davidson JA et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009;15:540-59.
28. Glucophage [package insert]. Princeton, NJ: Bristol Myers Squibb; 2009.
29. Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care 2011;34:1431-7.
30. Bowen ME. The relationship between body weight, frailty, and the disablement process. J Gerontol B Psychol Sci Soc Sci 2012;67:618-26.
31. Deusenberry CM, Coley KC, Korytkowski MT et al. Hypoglycemia in hospitalized patients treated with sulfonylureas. Pharmacotherapy 2012;32:613-7.
32. Gangji AS, Cukierman T, Gerstein HC et al. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care 2007;30:389-94. (Pubitemid 46198354)
33. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2012;60:616-31.
34. Micromedex® Healthcare Series [intranet database]. Version 2.0. Greenwood Village, CO: Thomson Healthcare.
35. Riedel AA, Heien H, Wogen J et al. Loss of glycemic control in patients with type 2 diabetes mellitus who were receiving initial metformin, sulfonylurea, or thiazolidinedione monotherapy. Pharmacotherapy 2007;27:1102-10. (Pubitemid 47173656)
36. Fu AZ, Qiu Y, Davies MJ et al. Initial sulfonylurea use and subsequent insulin therapy in older subjects with type 2 diabetes mellitus. Diabetes Ther 2012;3:12.
37. Yki-Järvinen H. Thiazolidinediones. N Engl J Med 2004;351: 1106-18.
38. Nesto RW, Bell D, Bonow RO et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004;27:256-63. (Pubitemid 38196741)
39. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71. (Pubitemid 46919772)
40. Graham DJ, Ouellet-Hellstrom R, MaCurdy TE et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 2010;304:411-8.
41. Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 2010;170:1191-201.
42. Schwartz AV, Sellmeyer DE, Vittinghoff E et al. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 2006;91:3349-54. (Pubitemid 44402103)
43. Bilik D, McEwen LN, Brown MB et al. Thiazolidinediones and fractures: evidence from translating research into action for diabetes. J Clin Endocrinol Metab 2010;95:4560-5.
44. Meier C, Kraenzlin ME, Bodmer M et al. Use of thiazolidinediones and fracture risk. Arch Intern Med 2008;168:820-5. (Pubitemid 351620084)
45. Grey A, Bolland M, Gamble G et al. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 2007;92:1305-10. (Pubitemid 46556402)
46. Habib ZA, Havstad SL, Wells K et al. Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2010;95:592-600.
47. Dormuth CR, Carney G, Carleton B et al. Thiazolidinediones and fractures in men and women. Arch Intern Med 2009;169:1395-402.
48. Kahn SE, Zinman B, Lachin JM et al. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 2008;31:845-51.
49. Lewis JD, Ferrara A, Peng T et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 2011;34:916-22.
50. Actos [package insert]. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; 2011.
51. Hsu J, Fung V, Price M et al. Medicare beneficiaries' knowledge of Part D prescription drug program benefits and responses to drug costs. JAMA 2008;299:1929-36. (Pubitemid 351574923)
52. Januvia [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2011.
53. Onglyza [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2011.
54. Tradjenta [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals; 2011.
55. Josse RG, Chiasson JL, Ryan EA et al. Acarbose in the treatment of elderly patients with type 2 diabetes. Diabetes Res Clin Pract 2003;59:37-42. (Pubitemid 35461908)
56. Neumiller JJ, Setter SM. Pharmacologic management of the older patient with type 2 diabetes mellitus. Am J Geriatr Pharmacother 2009;7:324-42.
57. Spinzi G, Amato A, Imperiali G et al. Constipation in the elderly: management strategies. Drugs Aging 2009;26:469-74.
58. Welchol [package insert]. Parsippany, NJ: Daiichi Sankyo, Inc.; 2012.
59. Buse JB, Rosenstock J, Sesti G et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374:39-47.
60. Buse JB, Bergenstal RM, Glass LC et al. Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2011;154:103-12.
61. Victoza [package insert]. Princeton, NJ: Novo Nordisk, Inc.; 2011.
62. Byetta [package insert]. San Diego, CA: Amylin Pharmaceuticals, Inc.; 2011.
63. Painter NA, Morello CM, Singh RF et al. An evidence-based and practical approach to using Bydureon™ in patients with type 2 diabetes. J Am Board Fam Med 2013;26:203-10.
64. Symlin [package insert]. San Diego, CA: Amylin Pharmaceuticals, Inc.; 2008.
65. Tanwani LK. Insulin therapy in the elderly patient with diabetes. Am J Geriatr Pharmacother 2011;9:24-36.
66. Garber AJ, Clauson P, Pedersen CB et al. Lower risk of hypoglycemia with insulin detemir than with neutral protamine Hagedorn insulin in older persons with type 2 diabetes: a pooled analysis of phase III trials. J Am Geriatr Soc 2007;55:1735-40. (Pubitemid 350043780)
67. Queale WS, Seidler AJ, Brancati FL. Glycemic control and sliding scale insulin use in medical inpatients with diabetes mellitus. Arch Intern Med 1997;157:545-52. (Pubitemid 27102713)
68. Kimball ES, Aagren M. Coverage of insulin delivery devices and basal insulin analogs by US managed care organizations. J Med Econ 2011;14:720-8.
69. Sinclair A, Morley JE, Rodriguez-Manas L et al. Diabetes Mellitus in Older People: Position Statement on behalf of the International Association of Gerontology and Geriatrics (IAGG), the European Diabetes Working Party for Older People (EDWPOP), and the International Task Force of Experts in Diabetes. J Am Med Dir Assoc 2012;13:497-502.
70. Glucotrol[package insert]. New York, NY: Pfizer Inc.; 2010.
71. Micronase[package insert]. New York, NY: Pfizer Inc.; 2010.
72. Avandia[package insert].Research Triangle Park, NC: GlaxoSmithKline; 2011.
73. Precose[package insert]. Wayne, NJ: Bayer HealthCare Pharmaceuticals; 2011.
74. Glyset[package insert]. New York, NY: Pfizer Inc.; 2010.
75. Humalog[package insert]. Indianapolis, IN: Lilly; 2011.
76. Lantus[package insert]. Bridgewater, NJ: Sanofi-aventis; 2010.
77. Levemir[package insert]. Princeton, NJ: NovoNordisk Inc.
78. Standards of medical care in diabetes-2014. Diabetes Care 2014;37:Suppl 1:S14-79.
79. American Geriatrics Society Expert Panel on the Care of Older Adults with Diabetes Mellitus. Moreno G, Mangione CM, Kimbro L et al. Guidelines abstracted from the American Geriatrics Society Guidelines for Improving the Care of the Older Adult with Diabetes Mellitus: 2013 Update. J Am Geriatr Soc 2013:61:2020-6.